Rapid Diagnostek
Hudson
About Rapid Diagnostek
Rapid Diagnostek formerly Intellignostics, has developed a patented, inexpensive, easy to use sensor appropriate for detecting bacteria, viruses, spores and disease biomarkers. Markets of opportunity include human and veterinary diagnostic, environmental, biohazard, bioterrorism, agricultural commodity, and food safety testing. Its technology offers remarkably faster and less expensive results than existing methods. Current diagnostic tests can take hours to days from the time a sample is taken to delivery of results. Rapid Diagnostek's IntelliProbe Immunosensor (IPI) platform can deliver results at the point of sampling in under 60 seconds. The sensor has performed as intended in the laboratory and the company is now developing a fully functioning device and initial assays to aggressively move towards commercialization.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $14.2M
- Last round: Series Unknown (Jan 2019)
- Website: rapiddiagnostek.com
- Phone: 763-710-7501
Industries & Categories
Agriculture, Biotechnology, Genetics, Health Diagnostics, Life Science
Social Profiles
Canonical: https://fsome.com/organization/rapid-diagnostek-2694874 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.